Efforts to shift more production of pharmaceuticals and APIs to the United States as a strategy for reducing drug shortages and ensuring access to needed medicines has gained strength in the White House and on Capitol Hill. The recent $2-trillion COVID economic stimulus legislation, which provides billions in assistance to US industry and individuals losing jobs, also supports exploration of federal “Buy American” policies, ostensibly to reduce US dependence on drugs and medical products imported from overseas.
